Develops, manufactures and markets a robust line of rapid diagnostic tests that address some of today's greatest healthcare challenges, including HIV and Hepatitis C.
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: MedMira Announces Grant of Employee Stock Options

Generic_profile
Rank: [?]
Treasurer
Points: [?]
569
Rating: [?]
Votes: 22 Score: 3.4
  • Currently 3.4/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

MedMira Announces Grant of Employee Stock Options

posted on Feb 28, 10 11:51AM

MedMira Announces Grant of Employee Stock Options

MedMira Announces Grant of Employee Stock Options
Halifax, Nova Scotia, January 5, 2009 – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that the Board of Directors granted a total of 1,585,000 options to purchase commons shares to its employees. Of this total, 450,000 options were issued to officers and managing directors. The options are at an exercise prices of
.10 per share and are exercisable for a period of five years. The grant is subject to the approval of the TSX Venture Exchange.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
MedMira Contacts:
Dr. James Smith, Investor Relations & Corporate Affairs
Tel: 902-450-1588
Email: ir@medmira.com
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com

New Message

Please login to post a reply

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now

President's D.D.

New feature: Hub Presidents can add important links here.